Featured Research

from universities, journals, and other organizations

Certain Combined Medications Following Heart Attack May Increase Risk Of Death

Date:
March 9, 2009
Source:
JAMA and Archives Journals
Summary:
Following an acute coronary syndrome such as a heart attack or unstable angina, patients who receive a medication to reduce the risk of gastrointestinal bleeding that may be associated with the use of the antiplatelet drug clopidogrel and aspirin have an increased risk of subsequent hospitalization for acute coronary syndrome or death, according to a new study.

Following an acute coronary syndrome such as a heart attack or unstable angina, patients who receive a medication to reduce the risk of gastrointestinal bleeding that may be associated with the use of the antiplatelet drug clopidogrel and aspirin have an increased risk of subsequent hospitalization for acute coronary syndrome or death, according to a new study.

Treatment with clopidogrel in addition to aspirin reduces recurrent cardiovascular events following hospitalization for acute coronary syndrome (ACS) for patients treated either medically or with angioplasty or stent placement. Proton pump inhibitor (PPI) medications are often prescribed at the start of treatment with clopidogrel, with the goal of reducing the risk of gastrointestinal tract bleeding while patients are taking dual-antiplatelet therapy. Recent studies, however, suggest that PPIs may reduce the effectiveness of clopidogrel, but the clinical significance of these findings to patients is not clear, according to background information in the article.

P. Michael Ho, M.D., Ph.D., of the Denver VA Medical Center, and colleagues evaluated the use of clopidogrel plus PPI following hospital discharge for ACS and compared rates of all-cause death and rehospitalization for ACS, between patients taking clopidogrel plus PPI vs. clopidogrel without PPI. The study included patients from 127 Veterans Affairs hospitals. Vital status information was available for all patients through September 30, 2006.

Of 8,205 patients with ACS taking clopidogrel after hospital discharge, 63.9 percent (n = 5,244) were prescribed PPI at discharge or during follow-up. Death or rehospitalization for ACS occurred in 29.8 percent of patients prescribed clopidogrel plus PPI and 20.8 percent of patients prescribed clopidogrel without PPI . Use of clopidogrel plus PPI at any point in time was associated with a 25 percent increased odds of death or rehospitalization for ACS compared with use of clopidogrel without PPI.

For the individual outcomes, the rates of recurrent hospitalization for ACS (14.6 percent vs. 6.9 percent) and revascularization procedures (15.5 percent vs. 11.9 percent) were higher among patients taking clopidogrel plus PPI compared with those taking clopidogrel without PPI. However, the risk of death was similar between the two groups.

"When patients were not taking clopidogrel after hospital discharge, a prescription for PPI was not associated with death or rehospitalization for ACS, supporting the hypothesis that the interaction of PPI and clopidogrel, rather than PPI itself, was associated with increased adverse outcomes," the authors write.

"… this study raises some concern about concomitant [accompanying] use of PPI medications and clopidogrel following hospitalization for ACS. While the risk estimates associated with clopidogrel plus PPI vs. clopidogrel without PPI were modest, the absolute number of adverse events attributable to this potential drug interaction is considerable when extrapolated to a population level, given how frequently PPI medications are prescribed to patients receiving dual-antiplatelet therapy," the researchers write. "Pending additional evidence, however, the results of this study may suggest that PPIs should be used for patients with a clear indication for the medication, such as history of gastrointestinal tract bleeding, consistent with current guideline recommendations, rather than routine prophylactic prescription. Alternative gastrointestinal tract medication regimens also may be considered until additional data regarding concomitant use of PPI and clopidogrel becomes available."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. P. Michael Ho; Thomas M. Maddox; Li Wang; Stephan D. Fihn; Robert L. Jesse; Eric D. Peterson; John S. Rumsfeld. Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome. JAMA, 2009;301(9):937-944 [link]

Cite This Page:

JAMA and Archives Journals. "Certain Combined Medications Following Heart Attack May Increase Risk Of Death." ScienceDaily. ScienceDaily, 9 March 2009. <www.sciencedaily.com/releases/2009/03/090303161307.htm>.
JAMA and Archives Journals. (2009, March 9). Certain Combined Medications Following Heart Attack May Increase Risk Of Death. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/03/090303161307.htm
JAMA and Archives Journals. "Certain Combined Medications Following Heart Attack May Increase Risk Of Death." ScienceDaily. www.sciencedaily.com/releases/2009/03/090303161307.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins